Charles River Laboratories International, Inc. Common Stock (CRL)
167.55
0.00 (0.00%)
Charles River Laboratories International is a global provider of laboratory services that support the pharmaceutical, biotechnology, and medical device industries
The company offers a comprehensive suite of research and development solutions, including essential support for drug discovery, safety assessment, and manufacturing. By providing innovative tools and technologies, as well as expertise in areas such as toxicology and genetic testing, Charles River plays a critical role in advancing biomedical research and helping clients develop and bring new therapies to market efficiently and effectively.
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSECRL) and its peers.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Let's delve into the developments on the US markets one hour before the close of the markets on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
Lab services company Charles River Laboratories (NYSECRL) reported Q4 CY2024 results exceeding the market’s revenue expectations, but sales fell by 1.1% year on year to $1.00 billion. Its non-GAAP profit of $2.66 per share was 5.1% above analysts’ consensus estimates.
Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Wall Street saw a modest uptick on Tuesday as investors turned their focus to upcoming US inflation data following a better-than-expected producer price index (PPI) report.
Charles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating margin dropped to 11.6% amid restructuring costs.
